Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06353126

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for living donor liver transplantation receive DEB-TACE 2 weeks prior to the surgery.

The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS);2) Pathological response rate (Pathological Response); 3) Proportion of patients completing living donor liver transplantation; 4) Adverse events related to DEB-TACE.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China

Location status: Recruiting

Location contact

Kang Associate chief physician

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-75 years;
  • Subjects with viral hepatitis or cirrhosis are clinically diagnosed according to AASLD standards, which require a history of viral hepatitis or cirrhosis combined with imaging examinations (enhanced CT, MRI, second-generation ultrasound contrast agents). When the tumor diameter is greater than 2 cm, a diagnosis can be made if one imaging technique shows typical arterial phase rapid enhancement and rapid washout. If the diameter is 1-2 cm, two imaging techniques must confirm this, or one imaging technique confirms it and alpha-fetoprotein (AFP) is greater than 400 ng/ml. For subjects who cannot be clinically diagnosed, histological or cytological biopsy confirmation is required; original biopsy records can also be used for diagnosis.
  • Child-Pugh score A-B grade;
  • Tumor present in the right lobe of the liver;
  • Liver cancer assessment meeting the "up to seven" criteria: the sum of tumor size and number does not exceed 7;
  • ECOG-PS score 0-1;
  • Scheduled for living donor liver transplantation as the primary treatment;
  • Signed informed consent form.

Exclusion criteria

  • Presence of definite cancer thrombi in the main portal vein, vena cava, or main bile duct;
  • Severe hepatic encephalopathy;
  • Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV);
  • Severe contrast agent allergy;
  • Irreversible hepatic artery to hepatic vein shunt;
  • Special types of anatomical variations (Asan portal vein type III);
  • Extrahepatic metastatic tumors;
  • Concurrent active hepatitis or severe infection;
  • Tumor dissemination or distant metastasis, expected survival <3 months;
  • Renal dysfunction, creatinine >176.8 umol/L or creatinine clearance rate <30ml/min;
  • White blood cell count <3.0x109/L, platelet count <50x106/L, and unable to correct;
  • Inability to tolerate surgical anesthesia (severe infection, cardiopulmonary insufficiency, cerebrovascular disease);
  • Severe psychiatric illness;
  • Other reasons deemed unsuitable for participation by the investigator.

Treatment and study plan

DEB-TACE

Procedure

DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).

During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells.

Primary outcomes

  1. Recurrence-free survival (RFS)

    Time frame: 2 years

    the time from DEB-TACE treatment until tumor recurrence in the original site, transplanted liver, other tissues and organs, or death, whichever occurs first.

Secondary outcomes

  1. Overall survival (OS)

    Time frame: 5 years

    the time from DEB-TACE treatment until death from any cause.

  2. Pathological response rate (Pathological Response)

    Time frame: 1 year

    at the time of the surgery

  3. Proportion of patients completing living donor liver transplantation

    Time frame: at the time of the surgery

    1 year

  4. Adverse events related to DEB-TACE

    Time frame: from DEB-TACE to the surgery

    2 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

RenJi Hospital

Other

Collaborators

  • Boston Scientific Corporation

Registry information

Official study title

A Prospective, Single Arm, Exploratory Study of Using Drug-eluting Beads Transarterial Chemoembolization Prior to Liver Transplantation in the Treatment of Hepatocellular Carcinoma

Important dates

Study start
2024
Primary completion
2025
Study completion
2027
First posted
Apr 8, 2024
Registry last updated
Oct 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.